Skip to main content
Top
Published in: Nutrition & Metabolism 1/2008

Open Access 01-12-2008 | Review

Role of cytochrome P450 in drug interactions

Author: Zakia Bibi

Published in: Nutrition & Metabolism | Issue 1/2008

Login to get access

Abstract

Drug-drug interactions have become an important issue in health care. It is now realized that many drug-drug interactions can be explained by alterations in the metabolic enzymes that are present in the liver and other extra-hepatic tissues. Many of the major pharmacokinetic interactions between drugs are due to hepatic cytochrome P450 (P450 or CYP) enzymes being affected by previous administration of other drugs. After coadministration, some drugs act as potent enzyme inducers, whereas others are inhibitors. However, reports of enzyme inhibition are very much more common. Understanding these mechanisms of enzyme inhibition or induction is extremely important in order to give appropriate multiple-drug therapies. In future, it may help to identify individuals at greatest risk of drug interactions and adverse events.
Literature
1.
go back to reference Guengerich FP: Characterization of human cytochrome P450 enzyme. FASEB Journal 1992,6(2):745-748. Guengerich FP: Characterization of human cytochrome P450 enzyme. FASEB Journal 1992,6(2):745-748.
2.
go back to reference Nelson DR, Kamataki T, Waxman DJ: The P450 superfamily: update on new sequences, gene mapping, accession numbers,early trivial names of enzymes, and nomenclature. DNA Cell Biol 1993,12(1):1-51. 10.1089/dna.1993.12.1CrossRef Nelson DR, Kamataki T, Waxman DJ: The P450 superfamily: update on new sequences, gene mapping, accession numbers,early trivial names of enzymes, and nomenclature. DNA Cell Biol 1993,12(1):1-51. 10.1089/dna.1993.12.1CrossRef
3.
go back to reference Nebert DW, Nelson DR, Coon MJ: The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. DNA Cell Biol 1991,10(1):1-14. 10.1089/dna.1991.10.1CrossRef Nebert DW, Nelson DR, Coon MJ: The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. DNA Cell Biol 1991,10(1):1-14. 10.1089/dna.1991.10.1CrossRef
4.
go back to reference Nakamura K, Goto F, Ray WA: Interethinic differences in genetic polymorphism of debrisoquin and mepheytoin hydroxylation between Japanese and Caucasian population. Clin Pharmacol Ther 1985,38(4):402-408. 10.1038/clpt.1985.194CrossRef Nakamura K, Goto F, Ray WA: Interethinic differences in genetic polymorphism of debrisoquin and mepheytoin hydroxylation between Japanese and Caucasian population. Clin Pharmacol Ther 1985,38(4):402-408. 10.1038/clpt.1985.194CrossRef
5.
go back to reference Wilkinson GR, Guengerich FP, Branch RA: Genetic polymorphism of S-mepheytoin hydroxylation. Pharmacology and Therapeutics 1989, 43: 53-76. 10.1016/0163-7258(89)90047-8CrossRef Wilkinson GR, Guengerich FP, Branch RA: Genetic polymorphism of S-mepheytoin hydroxylation. Pharmacology and Therapeutics 1989, 43: 53-76. 10.1016/0163-7258(89)90047-8CrossRef
6.
go back to reference Bertilsson L, Lou YQ, Du YL: Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mepheytoin. Clin Pharmacol Ther 1992,51(4):388-397. 10.1038/clpt.1992.38CrossRef Bertilsson L, Lou YQ, Du YL: Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mepheytoin. Clin Pharmacol Ther 1992,51(4):388-397. 10.1038/clpt.1992.38CrossRef
7.
go back to reference Wrighton SA, Stevens JC, Becker GW: Isolation and characterization of human liver cytochrome P450:2C19: correlation between 2C19 and S-mepheytoin hydrpxylation. Archives of Biochemistry and Biophysics 1993, 306: 240-245. 10.1006/abbi.1993.1506CrossRef Wrighton SA, Stevens JC, Becker GW: Isolation and characterization of human liver cytochrome P450:2C19: correlation between 2C19 and S-mepheytoin hydrpxylation. Archives of Biochemistry and Biophysics 1993, 306: 240-245. 10.1006/abbi.1993.1506CrossRef
8.
go back to reference Mehgoub A, Dring LG, Idle JR, Lancaster R, Smith RL: Polymorphic hydroxylation of debrisoquine in man. Lancet 1977, 2: 584-586. 10.1016/S0140-6736(77)91430-1CrossRef Mehgoub A, Dring LG, Idle JR, Lancaster R, Smith RL: Polymorphic hydroxylation of debrisoquine in man. Lancet 1977, 2: 584-586. 10.1016/S0140-6736(77)91430-1CrossRef
9.
go back to reference Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ: Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 1979,16(3):183-187. 10.1007/BF00562059CrossRef Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ: Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 1979,16(3):183-187. 10.1007/BF00562059CrossRef
10.
go back to reference Brásen K, Gram LF: Clinical significance of the sparteine/debrisoquine oxidation polymorphism. European Journal of Clinical Pharmacology 1989, 36: 537-547. 10.1007/BF00637732CrossRef Brásen K, Gram LF: Clinical significance of the sparteine/debrisoquine oxidation polymorphism. European Journal of Clinical Pharmacology 1989, 36: 537-547. 10.1007/BF00637732CrossRef
11.
go back to reference Meyer UA, Skoda RC, Zanger UM: The genetic polymorphism of debrisoquine/sparteine metabolism: molecular mechanisms. Pharmacology and Therapeutics 1990, 46: 297-308. 10.1016/0163-7258(90)90096-KCrossRef Meyer UA, Skoda RC, Zanger UM: The genetic polymorphism of debrisoquine/sparteine metabolism: molecular mechanisms. Pharmacology and Therapeutics 1990, 46: 297-308. 10.1016/0163-7258(90)90096-KCrossRef
12.
go back to reference Eichelbaum M, Gross : The genetic polymorphism of debrisoquine/sparteine metabolism. Pharmacology and Therapeutics 1990, 46: 377-394. 10.1016/0163-7258(90)90025-WCrossRef Eichelbaum M, Gross : The genetic polymorphism of debrisoquine/sparteine metabolism. Pharmacology and Therapeutics 1990, 46: 377-394. 10.1016/0163-7258(90)90025-WCrossRef
13.
go back to reference Lennard MS: Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal. Pharmacol Toxicol 1990,67(4):273-283. 10.1111/j.1600-0773.1990.tb00830.xCrossRef Lennard MS: Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal. Pharmacol Toxicol 1990,67(4):273-283. 10.1111/j.1600-0773.1990.tb00830.xCrossRef
14.
go back to reference Gonzalez FK, Meyer UA: Molecular genetics of the debrisoquine/sparteine metabolism. Clinical Pharmacology and Therapeutics 1991, 50: 233-238. 10.1038/clpt.1991.131CrossRef Gonzalez FK, Meyer UA: Molecular genetics of the debrisoquine/sparteine metabolism. Clinical Pharmacology and Therapeutics 1991, 50: 233-238. 10.1038/clpt.1991.131CrossRef
15.
go back to reference Okuda H, Nishiyama T, Ogura K: Drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. Drug Metabolism and Disposition 1997, 25: 270-273. Okuda H, Nishiyama T, Ogura K: Drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. Drug Metabolism and Disposition 1997, 25: 270-273.
16.
go back to reference Desgranges C, Razaka G, De Clercq E: Effect of (E) -5-(2-bromovinyl) uracil on the catabolism and antitumor activity of5-fluorouracil in rats and leukemic mice. Cancer Research 1986, 46: 1094-1101. Desgranges C, Razaka G, De Clercq E: Effect of (E) -5-(2-bromovinyl) uracil on the catabolism and antitumor activity of5-fluorouracil in rats and leukemic mice. Cancer Research 1986, 46: 1094-1101.
17.
go back to reference Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR Jr: Torsades de pointes occurring in association with terfenadine use. JAMA 1990, 264: 2788-2790. 10.1001/jama.264.21.2788CrossRef Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR Jr: Torsades de pointes occurring in association with terfenadine use. JAMA 1990, 264: 2788-2790. 10.1001/jama.264.21.2788CrossRef
18.
go back to reference Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR: Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 1993, 269: 1513-1518. 10.1001/jama.269.12.1513CrossRef Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR: Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 1993, 269: 1513-1518. 10.1001/jama.269.12.1513CrossRef
19.
go back to reference Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr: Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992,52(3):231-238. 10.1038/clpt.1992.135CrossRef Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr: Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992,52(3):231-238. 10.1038/clpt.1992.135CrossRef
20.
go back to reference Pohjola-Sintonen S, Viitasalo M, Toivonen L, Neuvonen P: Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. European Journal of Clinical Pharmacology 1993, 45: 191-193. 10.1007/BF00315505CrossRef Pohjola-Sintonen S, Viitasalo M, Toivonen L, Neuvonen P: Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. European Journal of Clinical Pharmacology 1993, 45: 191-193. 10.1007/BF00315505CrossRef
21.
go back to reference Mattila MJ: Alcohol and drug interactions. Annals of Medicine 1990, 22: 363-369. 10.3109/07853899009147921CrossRef Mattila MJ: Alcohol and drug interactions. Annals of Medicine 1990, 22: 363-369. 10.3109/07853899009147921CrossRef
22.
go back to reference Humphries TJ: Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole. Digestive Diseases and Sciences 1991, 36: C1665-C1669. 10.1007/BF01296606CrossRef Humphries TJ: Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole. Digestive Diseases and Sciences 1991, 36: C1665-C1669. 10.1007/BF01296606CrossRef
23.
go back to reference Andersson T: Omeprazole drug interaction studies. Clinical Pharmacokinetics 1991, 21: 195-212. 10.2165/00003088-199121030-00004CrossRef Andersson T: Omeprazole drug interaction studies. Clinical Pharmacokinetics 1991, 21: 195-212. 10.2165/00003088-199121030-00004CrossRef
24.
go back to reference Periti P, Mazzei T, Mini E, Novelli A: Pharmacokinetic drug interactions of macrolides. Clinical Pharmacokinetics 1992, 23: 106-131. 10.2165/00003088-199223020-00004CrossRef Periti P, Mazzei T, Mini E, Novelli A: Pharmacokinetic drug interactions of macrolides. Clinical Pharmacokinetics 1992, 23: 106-131. 10.2165/00003088-199223020-00004CrossRef
25.
go back to reference Gillum JG, Israel DS, Polk RE: Pharmacokinetic drug interactions with antimicrobial agents. Clinical Pharmacokinetics 1993, 25: 450-482. 10.2165/00003088-199325060-00005CrossRef Gillum JG, Israel DS, Polk RE: Pharmacokinetic drug interactions with antimicrobial agents. Clinical Pharmacokinetics 1993, 25: 450-482. 10.2165/00003088-199325060-00005CrossRef
26.
go back to reference Maurer PM, Bartkowski RR: Drug interactions of clinical significance with opioid analgesics. Drug Safety 1993, 8: 30-48. 10.2165/00002018-199308010-00005CrossRef Maurer PM, Bartkowski RR: Drug interactions of clinical significance with opioid analgesics. Drug Safety 1993, 8: 30-48. 10.2165/00002018-199308010-00005CrossRef
27.
go back to reference Finley PR: Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions. Annals of Pharmacotherapy 1994, 28: 359-1369. Finley PR: Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions. Annals of Pharmacotherapy 1994, 28: 359-1369.
28.
go back to reference Grange JM, Winstanley PA, Davies PD: Clinically significant drug interactions with antituberculosis agents. Drug Safety 1994, 11: 242-251. 10.2165/00002018-199411040-00003CrossRef Grange JM, Winstanley PA, Davies PD: Clinically significant drug interactions with antituberculosis agents. Drug Safety 1994, 11: 242-251. 10.2165/00002018-199411040-00003CrossRef
29.
go back to reference DeVane CL: Pharmacogenetics and drug metabolism of newer antidepressant agents. Journal of Clinical Psychiatry 1994,55(Suppl):38-47. DeVane CL: Pharmacogenetics and drug metabolism of newer antidepressant agents. Journal of Clinical Psychiatry 1994,55(Suppl):38-47.
30.
go back to reference Shen WW: Cytochrome P450 monooxygenases and interactions of psychotropic drugs: a five-year update. Int J Psychiatry Med 1995,25(3):277-290. 10.2190/29NP-2XPN-X0ME-MQWUCrossRef Shen WW: Cytochrome P450 monooxygenases and interactions of psychotropic drugs: a five-year update. Int J Psychiatry Med 1995,25(3):277-290. 10.2190/29NP-2XPN-X0ME-MQWUCrossRef
31.
go back to reference Kivisto KT, Kroemer HK, Eichelbaum M: The role of human cytochrome P450 enzymes in the metabolism of anticancer agents:implications for drug interactions. British Journal of Clinical Pharmacology 1995, 40: 523-530. 10.1111/j.1365-2125.1995.tb05796.xCrossRef Kivisto KT, Kroemer HK, Eichelbaum M: The role of human cytochrome P450 enzymes in the metabolism of anticancer agents:implications for drug interactions. British Journal of Clinical Pharmacology 1995, 40: 523-530. 10.1111/j.1365-2125.1995.tb05796.xCrossRef
32.
go back to reference Levy RH: Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia 1995,36(Suppl 5):S8-S13. 10.1111/j.1528-1157.1995.tb06007.xCrossRef Levy RH: Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia 1995,36(Suppl 5):S8-S13. 10.1111/j.1528-1157.1995.tb06007.xCrossRef
33.
go back to reference Ketter TA, Flockhart DA, Post RM: The emerging role of cytochrome P450, 3A in psychoI?pharmacology. Journal of Clinical Psychopharmacology 1995, 15: 387-398. 10.1097/00004714-199512000-00002CrossRef Ketter TA, Flockhart DA, Post RM: The emerging role of cytochrome P450, 3A in psychoI?pharmacology. Journal of Clinical Psychopharmacology 1995, 15: 387-398. 10.1097/00004714-199512000-00002CrossRef
34.
go back to reference Von Rosensteil NA, Adam D: Macrolide antibacterials. Drug interactions of clinical significance. Drug Safety 1995, 13: 105-122. 10.2165/00002018-199513020-00005CrossRef Von Rosensteil NA, Adam D: Macrolide antibacterials. Drug interactions of clinical significance. Drug Safety 1995, 13: 105-122. 10.2165/00002018-199513020-00005CrossRef
35.
go back to reference Ciummo PE, Katz NL: Interactions and drug-metabolizing enzymes. American Pharmacy 1995, 35: 41-51. Ciummo PE, Katz NL: Interactions and drug-metabolizing enzymes. American Pharmacy 1995, 35: 41-51.
36.
go back to reference Slaughter RL, Edwards DJ: Recent advances: the cytochrome P450 enzymes. Annals of Pharmacotherapy 1995, 29: 619-624. Slaughter RL, Edwards DJ: Recent advances: the cytochrome P450 enzymes. Annals of Pharmacotherapy 1995, 29: 619-624.
37.
go back to reference Brosen K: Drug interactions and the cytochrome P450: system. The Role of Cytochrome P4501A2. Clinical Pharmacokinetics 1995,20(29 Suppl 1):25. Brosen K: Drug interactions and the cytochrome P450: system. The Role of Cytochrome P4501A2. Clinical Pharmacokinetics 1995,20(29 Suppl 1):25.
38.
go back to reference Ereshefsky L, Riesenman C, Lam YW: Antidepressant drug interactions and the cytochrome P450: system. The Role of Cytochrome P450 2D6. Clin Pharmacokinet 1995, 29 Suppl 1: 10-18. Discussion 18-19CrossRef Ereshefsky L, Riesenman C, Lam YW: Antidepressant drug interactions and the cytochrome P450: system. The Role of Cytochrome P450 2D6. Clin Pharmacokinet 1995, 29 Suppl 1: 10-18. Discussion 18-19CrossRef
39.
go back to reference Flockhart DA: Drug interactions and the cytochrome P450: system. The role of cytochrome P4502C19. Clin Pharmacokinet 1995, 29 Suppl 1: 45-52.CrossRef Flockhart DA: Drug interactions and the cytochrome P450: system. The role of cytochrome P4502C19. Clin Pharmacokinet 1995, 29 Suppl 1: 45-52.CrossRef
40.
go back to reference Von Moltke LL, Greenblatt DJ, Schmider J, Harmatz JS, Shader RI: Metabolism of drugs by cytochrome P450, 3A isoforms. Implications for drug interactions in psychopharmacology. Clin Pharmacokinet 1995, 29 Suppl 1: 33-43. Discussion 43-44CrossRef Von Moltke LL, Greenblatt DJ, Schmider J, Harmatz JS, Shader RI: Metabolism of drugs by cytochrome P450, 3A isoforms. Implications for drug interactions in psychopharmacology. Clin Pharmacokinet 1995, 29 Suppl 1: 33-43. Discussion 43-44CrossRef
41.
go back to reference Harder S, Thurmann P: Clinically important drug interactions with anticoagulants. An update. Clinical Pharmacokinetics 1996, 30: 416-444. 10.2165/00003088-199630060-00002CrossRef Harder S, Thurmann P: Clinically important drug interactions with anticoagulants. An update. Clinical Pharmacokinetics 1996, 30: 416-444. 10.2165/00003088-199630060-00002CrossRef
42.
go back to reference Borcherding SM, Stevens R, Nicholas RA, Corley CR, Self T: Quinolones: a practical review of clinical uses, dosing considerations, and drug interactions. Journal of Family Practice 1996, 42: 69-78. Borcherding SM, Stevens R, Nicholas RA, Corley CR, Self T: Quinolones: a practical review of clinical uses, dosing considerations, and drug interactions. Journal of Family Practice 1996, 42: 69-78.
43.
go back to reference Taburet AM, Singlas E: Drug interactions with antiviral drugs. Clinical Pharmacokinetics 1996, 30: 385-401. 10.2165/00003088-199630050-00005CrossRef Taburet AM, Singlas E: Drug interactions with antiviral drugs. Clinical Pharmacokinetics 1996, 30: 385-401. 10.2165/00003088-199630050-00005CrossRef
44.
go back to reference Ereshefsky L: Pharmacokinetics and drug interactions: update for new antipsychotics. Journal of Clinical Psychiatry 1996,57(Suppl 11):12-25. Ereshefsky L: Pharmacokinetics and drug interactions: update for new antipsychotics. Journal of Clinical Psychiatry 1996,57(Suppl 11):12-25.
45.
go back to reference Ereshefsky L, Riesenman C, Lam YW: Serotonin selective reuptake inhibitor drug interactions and the cytochrome P450system. Journal of Clinical Psychiatry 1996,57(Suppl 8):17-24. Ereshefsky L, Riesenman C, Lam YW: Serotonin selective reuptake inhibitor drug interactions and the cytochrome P450system. Journal of Clinical Psychiatry 1996,57(Suppl 8):17-24.
46.
go back to reference Nemeroff CB, DeVane CL, Pollock BG: Newer antidepressants and the cytochrome P450 system. American Journal of Psychiatry 1996, 135: 311-320. Nemeroff CB, DeVane CL, Pollock BG: Newer antidepressants and the cytochrome P450 system. American Journal of Psychiatry 1996, 135: 311-320.
47.
go back to reference Watkins VS, Polk RE, Stotka JL: Drug interactions of macrolides: emphasis on dirithromycin. Annals of Pharmacotherapy 1997, 31: 349-356. Watkins VS, Polk RE, Stotka JL: Drug interactions of macrolides: emphasis on dirithromycin. Annals of Pharmacotherapy 1997, 31: 349-356.
48.
go back to reference Paterson DL, Singh N: Interactions between tacrolimus and antimicrobial agents. Clinical Infectious Diseases 1997, 25: 1430-1440. 10.1086/516138CrossRef Paterson DL, Singh N: Interactions between tacrolimus and antimicrobial agents. Clinical Infectious Diseases 1997, 25: 1430-1440. 10.1086/516138CrossRef
49.
go back to reference Virani A, Mailis A, Shapiro LE, Shear NH: Drug interactions in human neuropathic pain pharmacoI?therapy. Pain 1997, 73: 3-13. 10.1016/S0304-3959(97)00041-9CrossRef Virani A, Mailis A, Shapiro LE, Shear NH: Drug interactions in human neuropathic pain pharmacoI?therapy. Pain 1997, 73: 3-13. 10.1016/S0304-3959(97)00041-9CrossRef
50.
go back to reference Mitchell PB: Drug interactions of clinical significance with selective serotonin reuptake inhibitors. Drug Safety 1997, 17: 390-406. 10.2165/00002018-199717060-00005CrossRef Mitchell PB: Drug interactions of clinical significance with selective serotonin reuptake inhibitors. Drug Safety 1997, 17: 390-406. 10.2165/00002018-199717060-00005CrossRef
51.
go back to reference Mignat C: Clinically significant drug interactions with new immunosuppressive agents. Drug Safety 1997, 16: 267-278. 10.2165/00002018-199716040-00004CrossRef Mignat C: Clinically significant drug interactions with new immunosuppressive agents. Drug Safety 1997, 16: 267-278. 10.2165/00002018-199716040-00004CrossRef
52.
go back to reference Singer MI, Shapiro LE, Shear NH: Cytochrome P-450, 3A: interactions with dermatologic therapies. Journal of the American Academy of Dermatology 1997, 37: 765-771. 10.1016/S0190-9622(97)70115-4CrossRef Singer MI, Shapiro LE, Shear NH: Cytochrome P-450, 3A: interactions with dermatologic therapies. Journal of the American Academy of Dermatology 1997, 37: 765-771. 10.1016/S0190-9622(97)70115-4CrossRef
53.
go back to reference Unge P, Andersson T: Drug interactions with proton pump inhibitors. Drug Safety 1997, 16: 171-179. 10.2165/00002018-199716030-00003CrossRef Unge P, Andersson T: Drug interactions with proton pump inhibitors. Drug Safety 1997, 16: 171-179. 10.2165/00002018-199716030-00003CrossRef
54.
go back to reference Fraser AG: Pharmacokinetic interactions between alcohol and other drugs. Clinical Pharmacokinetics 1997, 33: 79-90. 10.2165/00003088-199733020-00001CrossRef Fraser AG: Pharmacokinetic interactions between alcohol and other drugs. Clinical Pharmacokinetics 1997, 33: 79-90. 10.2165/00003088-199733020-00001CrossRef
55.
go back to reference Sproule BA, Naranjo CA, Brenmer KE, Hassan PC: Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clinical Pharmacokinetics 1997, 33: 454-471. 10.2165/00003088-199733060-00004CrossRef Sproule BA, Naranjo CA, Brenmer KE, Hassan PC: Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clinical Pharmacokinetics 1997, 33: 454-471. 10.2165/00003088-199733060-00004CrossRef
56.
go back to reference Guengerich FP: Role of cytochrome P450 enzymes. Advances in Pharmacology 1997, 4: 37-35. Guengerich FP: Role of cytochrome P450 enzymes. Advances in Pharmacology 1997, 4: 37-35.
57.
go back to reference Albengres E, Le Louet H, Tillement JP: Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf 1998,18(2):83-97. 10.2165/00002018-199818020-00001CrossRef Albengres E, Le Louet H, Tillement JP: Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf 1998,18(2):83-97. 10.2165/00002018-199818020-00001CrossRef
58.
go back to reference Cupp MJ, Tracy TS: Cytochrome P450: new nomenclature and clinical implications. American Family Physician 1998, 57: 107-116. Cupp MJ, Tracy TS: Cytochrome P450: new nomenclature and clinical implications. American Family Physician 1998, 57: 107-116.
59.
go back to reference Baker GB, Fang J, Sinha S, Coutts RT: Metabolic drug interactions with selective serotonin reuptake inhibitor (SSRI)antidepressants. Neuroscience and Biobehavioral Reviews 1998, 22: 325-333. 10.1016/S0149-7634(97)00018-3CrossRef Baker GB, Fang J, Sinha S, Coutts RT: Metabolic drug interactions with selective serotonin reuptake inhibitor (SSRI)antidepressants. Neuroscience and Biobehavioral Reviews 1998, 22: 325-333. 10.1016/S0149-7634(97)00018-3CrossRef
60.
go back to reference McLeod HL: Clinically relevant drug-drug interactions in oncolog. British Journal of Clinical Pharmacology 1998, 45: 539-544. 10.1046/j.1365-2125.1998.00719.xCrossRef McLeod HL: Clinically relevant drug-drug interactions in oncolog. British Journal of Clinical Pharmacology 1998, 45: 539-544. 10.1046/j.1365-2125.1998.00719.xCrossRef
61.
go back to reference Miners JO, Birkett DJ: Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. British Journal of Clinical Pharmacology 1998, 45: 525-538. 10.1046/j.1365-2125.1998.00721.xCrossRef Miners JO, Birkett DJ: Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. British Journal of Clinical Pharmacology 1998, 45: 525-538. 10.1046/j.1365-2125.1998.00721.xCrossRef
62.
go back to reference Negro RD: Pharmacokinetic drug interactions with anti-ulcer drugs. Clinical Pharmacokinetics 1998, 35: 135-150. 10.2165/00003088-199835020-00003CrossRef Negro RD: Pharmacokinetic drug interactions with anti-ulcer drugs. Clinical Pharmacokinetics 1998, 35: 135-150. 10.2165/00003088-199835020-00003CrossRef
63.
go back to reference Michalets EL: Update: clinically significant cytochrome P450 drug interactions. Pharmacotherapy 1998,18(1):84-112. Michalets EL: Update: clinically significant cytochrome P450 drug interactions. Pharmacotherapy 1998,18(1):84-112.
64.
go back to reference Dossing M, Pilsgaard H, Rasmussen B, Poulsen HE: Time course of phenobarbital and cimetidine mediated changes in hepatic drug metabolism. European Journal of Clinical Pharmacology 1983, 25: 215-222. 10.1007/BF00543794CrossRef Dossing M, Pilsgaard H, Rasmussen B, Poulsen HE: Time course of phenobarbital and cimetidine mediated changes in hepatic drug metabolism. European Journal of Clinical Pharmacology 1983, 25: 215-222. 10.1007/BF00543794CrossRef
65.
go back to reference Von MoltkeLL, Greenblatt DJ, Schmider J, Wright CE, Harmatz JS, Shader RI: In vitro approaches to predicting drug interactions in vivo. Biochemical Pharmacology 1998, 55: 113-122. 10.1016/S0006-2952(97)00239-6CrossRef Von MoltkeLL, Greenblatt DJ, Schmider J, Wright CE, Harmatz JS, Shader RI: In vitro approaches to predicting drug interactions in vivo. Biochemical Pharmacology 1998, 55: 113-122. 10.1016/S0006-2952(97)00239-6CrossRef
66.
go back to reference Guengerich FP, Gillam EM, Shimada T: New applications of bacterial systems to problems in toxicology. Critical Reviews in Toxicology 1996, 26: 551-583. 10.3109/10408449609037477CrossRef Guengerich FP, Gillam EM, Shimada T: New applications of bacterial systems to problems in toxicology. Critical Reviews in Toxicology 1996, 26: 551-583. 10.3109/10408449609037477CrossRef
67.
go back to reference Markowitz JS, Wells BG, Carson WH: Interactions between antipsychotic and antihypertensive drugs. Annals of Pharmacotherapy 1995, 29: 603-609. Markowitz JS, Wells BG, Carson WH: Interactions between antipsychotic and antihypertensive drugs. Annals of Pharmacotherapy 1995, 29: 603-609.
68.
go back to reference Bossche H, Koymans L, Moereels H: P450 inhibitors of use in medical treatment: focus on mechanisms of action. Pharmacology and Therapeutics 1995, 67: 79-100. 10.1016/0163-7258(95)00011-5CrossRef Bossche H, Koymans L, Moereels H: P450 inhibitors of use in medical treatment: focus on mechanisms of action. Pharmacology and Therapeutics 1995, 67: 79-100. 10.1016/0163-7258(95)00011-5CrossRef
69.
go back to reference Murray M: Drug-mediated inactivation of cytochrome P450. Clinical and Experimental Pharmacology and Physiology 1997, 24: 465-470. 10.1111/j.1440-1681.1997.tb01228.xCrossRef Murray M: Drug-mediated inactivation of cytochrome P450. Clinical and Experimental Pharmacology and Physiology 1997, 24: 465-470. 10.1111/j.1440-1681.1997.tb01228.xCrossRef
70.
go back to reference Wagner F, Kalusche D, Trenk D, Jahnchen E, Roskamm H: Drug interaction between propafenone and metoprolol. British Journal of Clinical Pharmacology 1987, 24: 213-220. 10.1111/j.1365-2125.1987.tb03164.xCrossRef Wagner F, Kalusche D, Trenk D, Jahnchen E, Roskamm H: Drug interaction between propafenone and metoprolol. British Journal of Clinical Pharmacology 1987, 24: 213-220. 10.1111/j.1365-2125.1987.tb03164.xCrossRef
71.
go back to reference Markowitz JS, Wells BG, Carson WH: Interactions between antipsychotic and antihypertensive drugs. Annals of Pharmacotherapy 1995, 29: 603-609. Markowitz JS, Wells BG, Carson WH: Interactions between antipsychotic and antihypertensive drugs. Annals of Pharmacotherapy 1995, 29: 603-609.
72.
go back to reference Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S: Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. Journal of Clinical Psychopharmacology 1994, 14: 90-98. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S: Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. Journal of Clinical Psychopharmacology 1994, 14: 90-98.
73.
go back to reference Zomorodi K, Houston JB: Effect of omeprazole on diazepam disposition in the rat: in vitro and in vivo studies. Pharmaceutical Research 1995, 12: 1642-1646. 10.1023/A:1016241000480CrossRef Zomorodi K, Houston JB: Effect of omeprazole on diazepam disposition in the rat: in vitro and in vivo studies. Pharmaceutical Research 1995, 12: 1642-1646. 10.1023/A:1016241000480CrossRef
74.
go back to reference Meyer UA: Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions. Eur J Gastroenterol Hepatol 1996, 8 Suppl 1: S21-S25. 10.1097/00042737-199610001-00005CrossRef Meyer UA: Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions. Eur J Gastroenterol Hepatol 1996, 8 Suppl 1: S21-S25. 10.1097/00042737-199610001-00005CrossRef
75.
go back to reference Zomorodi K, Houston JB: Diazepam-omeprazole inhibition interaction: an in vitro investigation using human liver microsomes. British Journal of Clinical Pharmacology 1996, 42: 157-162. 10.1046/j.1365-2125.1996.03563.xCrossRef Zomorodi K, Houston JB: Diazepam-omeprazole inhibition interaction: an in vitro investigation using human liver microsomes. British Journal of Clinical Pharmacology 1996, 42: 157-162. 10.1046/j.1365-2125.1996.03563.xCrossRef
76.
go back to reference Jones TE, Morris RG: Diltiazem does not always increase blood cyclosporin concentration. British Journal of Clinical Pharmacology 1996, 42: 642-644. 10.1111/j.1365-2125.1996.tb00062.xCrossRef Jones TE, Morris RG: Diltiazem does not always increase blood cyclosporin concentration. British Journal of Clinical Pharmacology 1996, 42: 642-644. 10.1111/j.1365-2125.1996.tb00062.xCrossRef
77.
go back to reference Campana C, Regazzi MB, Buggia I, Molinaro M: Clinically significant drug interactions with cyclosporine. Clinical Pharmacokinetics 1996, 30: 141-179. 10.2165/00003088-199630020-00004CrossRef Campana C, Regazzi MB, Buggia I, Molinaro M: Clinically significant drug interactions with cyclosporine. Clinical Pharmacokinetics 1996, 30: 141-179. 10.2165/00003088-199630020-00004CrossRef
78.
go back to reference Jones TE, Morris RG, Mathew TH: Diltiazem-cyclosporin pharmacokinetic interaction: dose-response relationship. British Journal of Clinical Pharmacology 1997, 44: 499-504. 10.1046/j.1365-2125.1997.t01-1-00616.xCrossRef Jones TE, Morris RG, Mathew TH: Diltiazem-cyclosporin pharmacokinetic interaction: dose-response relationship. British Journal of Clinical Pharmacology 1997, 44: 499-504. 10.1046/j.1365-2125.1997.t01-1-00616.xCrossRef
79.
go back to reference Nahata M: Drug interactions with azithromycin and the macrolides: an overview. Journal of Antimicrobial Chemotherapy 1996,37(Suppl C):133-142. 10.1093/jac/37.suppl_C.133CrossRef Nahata M: Drug interactions with azithromycin and the macrolides: an overview. Journal of Antimicrobial Chemotherapy 1996,37(Suppl C):133-142. 10.1093/jac/37.suppl_C.133CrossRef
80.
go back to reference Gurevitz SL: Erythromycin: drug interactions. Journal of Dental Hygiene 1997, 71: 159-161. Gurevitz SL: Erythromycin: drug interactions. Journal of Dental Hygiene 1997, 71: 159-161.
81.
go back to reference Stafstrom CE, Nohria V, Loganbill H, Nahouraii R, Boustany RM, DeLong GR: Erythromycin-induced carbamazepine toxicity: a continuing problem. Arch Pediatr Adolesc Med 1995,149(1):99-101. 10.1001/archpedi.1995.02170130101025CrossRef Stafstrom CE, Nohria V, Loganbill H, Nahouraii R, Boustany RM, DeLong GR: Erythromycin-induced carbamazepine toxicity: a continuing problem. Arch Pediatr Adolesc Med 1995,149(1):99-101. 10.1001/archpedi.1995.02170130101025CrossRef
82.
go back to reference Levy RH: Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia 1995,36(Suppl 5):S8-S13. 10.1111/j.1528-1157.1995.tb06007.xCrossRef Levy RH: Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia 1995,36(Suppl 5):S8-S13. 10.1111/j.1528-1157.1995.tb06007.xCrossRef
83.
go back to reference Mota CR, Carvalho C, Mota C, Ferreira P, Vilarinho A, Pereira E: Severe carbamazepine toxicity induced by concurrent erythromycin therapy. Eur J Pediatr 1996,155(4):345. 10.1007/BF02002727CrossRef Mota CR, Carvalho C, Mota C, Ferreira P, Vilarinho A, Pereira E: Severe carbamazepine toxicity induced by concurrent erythromycin therapy. Eur J Pediatr 1996,155(4):345. 10.1007/BF02002727CrossRef
84.
go back to reference Lown KS, Thummel KE, Benedict PE: The erythromycin breath test predicts the clearance of midazolam. Clin Pharmacol Ther 1995,57(1):16-24. 10.1016/0009-9236(95)90261-9CrossRef Lown KS, Thummel KE, Benedict PE: The erythromycin breath test predicts the clearance of midazolam. Clin Pharmacol Ther 1995,57(1):16-24. 10.1016/0009-9236(95)90261-9CrossRef
85.
go back to reference Zimmermann T, Yeates RA, Laufen H, Scharp EF, Leitold M, Wildfeuer A: Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam. Arzneimittelforschung 1996,46(2):213-217. Zimmermann T, Yeates RA, Laufen H, Scharp EF, Leitold M, Wildfeuer A: Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam. Arzneimittelforschung 1996,46(2):213-217.
86.
go back to reference Yeates RA, Laufen H, Zimmermann T, Schumacher T: Pharmacokinetic and pharmacodynamic interaction study between midazolam and the macrolide antibiotics, erythromycin, clarithromycin, and the azalide azithromycin. Int J Clin Pharmacol Ther 1997,35(12):577-579. Yeates RA, Laufen H, Zimmermann T, Schumacher T: Pharmacokinetic and pharmacodynamic interaction study between midazolam and the macrolide antibiotics, erythromycin, clarithromycin, and the azalide azithromycin. Int J Clin Pharmacol Ther 1997,35(12):577-579.
87.
go back to reference Campana C, Regazzi MB, Buggia I, Molinaro M: Clinically significant drug interactions with cyclosporin. An update. Clinical Pharmacokinetics 1996, 30: 141-179. 10.2165/00003088-199630020-00004CrossRef Campana C, Regazzi MB, Buggia I, Molinaro M: Clinically significant drug interactions with cyclosporin. An update. Clinical Pharmacokinetics 1996, 30: 141-179. 10.2165/00003088-199630020-00004CrossRef
88.
go back to reference Rodrigues AD, Mulford DJ, Lee RD: In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P450:3A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices. Drug Metabolism and Disposition 1995, 23: 765-775. Rodrigues AD, Mulford DJ, Lee RD: In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P450:3A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices. Drug Metabolism and Disposition 1995, 23: 765-775.
89.
go back to reference Ling KH, Leeson GA, Burmaster SD, Hook RH, Reith MK, Cheng LK: Metabolism of terfenadine associated with CYP3A activity in human hepatic microsomes. Drug Metab Dispos 1995,23(6):631-636. Ling KH, Leeson GA, Burmaster SD, Hook RH, Reith MK, Cheng LK: Metabolism of terfenadine associated with CYP3A activity in human hepatic microsomes. Drug Metab Dispos 1995,23(6):631-636.
90.
go back to reference Somogyi A, Gugler A: Drug interactions with cimetidine. Clinical Pharmacokinetics 1982, 7: 23-41. 10.2165/00003088-198207010-00002CrossRef Somogyi A, Gugler A: Drug interactions with cimetidine. Clinical Pharmacokinetics 1982, 7: 23-41. 10.2165/00003088-198207010-00002CrossRef
91.
go back to reference Somogyi A, Muirhead M: Pharmacokinetic interactions of cimetidine. Clinical Pharmacokinetics 1987, 12: 321-366. 10.2165/00003088-198712050-00002CrossRef Somogyi A, Muirhead M: Pharmacokinetic interactions of cimetidine. Clinical Pharmacokinetics 1987, 12: 321-366. 10.2165/00003088-198712050-00002CrossRef
92.
go back to reference Maurice M, Pichard L, Daujat M: Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB Journal 1992, 6: 752-758. Maurice M, Pichard L, Daujat M: Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB Journal 1992, 6: 752-758.
93.
go back to reference Ortiz de Montellano PR, Kunze KL, Yost GS, Mico BA: Self-catalyzed destruction of cytochrome P-450: covalent binding of ethynyl sterols to prosthetic heme. Proceedings of the National Academy of Sciences of the United States of America 1979, 76: 746-749. 10.1073/pnas.76.2.746CrossRef Ortiz de Montellano PR, Kunze KL, Yost GS, Mico BA: Self-catalyzed destruction of cytochrome P-450: covalent binding of ethynyl sterols to prosthetic heme. Proceedings of the National Academy of Sciences of the United States of America 1979, 76: 746-749. 10.1073/pnas.76.2.746CrossRef
94.
go back to reference Walubo A, Aboo A: Phenytoin toxicity due to concomitant antituberculosis therapy. South African Medical Journal 1995, 85: 1175-1176. Walubo A, Aboo A: Phenytoin toxicity due to concomitant antituberculosis therapy. South African Medical Journal 1995, 85: 1175-1176.
95.
go back to reference Back DJ, Orme ML: Pharmacokinetic drug interactions with oral contraceptives. Clinical PharmacoI kinetics 1990, 8: 472-484.CrossRef Back DJ, Orme ML: Pharmacokinetic drug interactions with oral contraceptives. Clinical PharmacoI kinetics 1990, 8: 472-484.CrossRef
96.
go back to reference Guengerich FP: Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chemical Research in Toxicology 1990, 3: 363-371. 10.1021/tx00016a015CrossRef Guengerich FP: Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chemical Research in Toxicology 1990, 3: 363-371. 10.1021/tx00016a015CrossRef
97.
go back to reference Gan LS, Acebo AL, Alworth WL: 1-Ethynylpyrene, a suicide inhibitor of cytochrome P-450 dependent benzo[a]pyrene hydroxylase activity in liver microsomes. Biochemistry 1984, 23: 3827-3836. 10.1021/bi00312a006CrossRef Gan LS, Acebo AL, Alworth WL: 1-Ethynylpyrene, a suicide inhibitor of cytochrome P-450 dependent benzo[a]pyrene hydroxylase activity in liver microsomes. Biochemistry 1984, 23: 3827-3836. 10.1021/bi00312a006CrossRef
98.
go back to reference Venkatesan K: Pharmacokinetic drug interactions with rifampicin. Clinical Pharmacokinetics 1992, 22: 47-65. 10.2165/00003088-199222010-00005CrossRef Venkatesan K: Pharmacokinetic drug interactions with rifampicin. Clinical Pharmacokinetics 1992, 22: 47-65. 10.2165/00003088-199222010-00005CrossRef
99.
go back to reference Lee KH, Shin JG, Chong WS: Time course of the changes in prednisolone pharmacokinetics after co-administration or discontinuation of rifampin. European Journal of Clinical Pharmacology 1993, 93: 45287-28987. Lee KH, Shin JG, Chong WS: Time course of the changes in prednisolone pharmacokinetics after co-administration or discontinuation of rifampin. European Journal of Clinical Pharmacology 1993, 93: 45287-28987.
100.
go back to reference Burger DM, Meenhorst PL, Koks CH, Beijnen JH: Pharmacokinetic interaction between rifampin and zidovudine. Antimicrobial Agents and Chemotherapy 1993, 37: 1426-1431. 10.1128/AAC.37.7.1426CrossRef Burger DM, Meenhorst PL, Koks CH, Beijnen JH: Pharmacokinetic interaction between rifampin and zidovudine. Antimicrobial Agents and Chemotherapy 1993, 37: 1426-1431. 10.1128/AAC.37.7.1426CrossRef
101.
go back to reference Grange JM, Winstanley PA, Davies PD: Clinically significant drug interactions with antituberculosis agents. Drug Safety 1994, 11: 242-251. 10.2165/00002018-199411040-00003CrossRef Grange JM, Winstanley PA, Davies PD: Clinically significant drug interactions with antituberculosis agents. Drug Safety 1994, 11: 242-251. 10.2165/00002018-199411040-00003CrossRef
102.
go back to reference Koselj M, Bren A, Kandus A, Kovac D: Drug interactions between cyclosporine and rifampicin, erythromycin, and azoles in kidney recipients with opportunistic infections. Transplantation Proceedings 1994, 26: 2823-2824. Koselj M, Bren A, Kandus A, Kovac D: Drug interactions between cyclosporine and rifampicin, erythromycin, and azoles in kidney recipients with opportunistic infections. Transplantation Proceedings 1994, 26: 2823-2824.
103.
go back to reference Holtbecker N, Fromm MF, Kroemer HK, Ohnhaus EE, Heidemann H: The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. Drug Metab Dispos 1996,24(10):1121-1123. Holtbecker N, Fromm MF, Kroemer HK, Ohnhaus EE, Heidemann H: The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. Drug Metab Dispos 1996,24(10):1121-1123.
104.
go back to reference Li AP, Reith MK, Rasmussen A: Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin. Chemico-Biological Interactions 1997, 107: 17-30. 10.1016/S0009-2797(97)00071-9CrossRef Li AP, Reith MK, Rasmussen A: Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin. Chemico-Biological Interactions 1997, 107: 17-30. 10.1016/S0009-2797(97)00071-9CrossRef
105.
go back to reference Fromm MF, Eckhardt K, Li S: Loss of analgesic effect of morphine due to coadministration of rifampin. Pain 1997, 72: 261-267. 10.1016/S0304-3959(97)00044-4CrossRef Fromm MF, Eckhardt K, Li S: Loss of analgesic effect of morphine due to coadministration of rifampin. Pain 1997, 72: 261-267. 10.1016/S0304-3959(97)00044-4CrossRef
106.
go back to reference Fromm MF, Busse D, Kroemer HK, Eichelbaum M: Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 1997, 24: 796-801. 10.1002/hep.510240407CrossRef Fromm MF, Busse D, Kroemer HK, Eichelbaum M: Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 1997, 24: 796-801. 10.1002/hep.510240407CrossRef
107.
go back to reference Fleishaker JC, Pearson LK, Peters GR: Gender does not affect the degree of duction of tirilazad clearance by Phenobarbital. European Journal of Clinical Pharmacology 1996, 50: 139-145. 10.1007/s002280050082CrossRef Fleishaker JC, Pearson LK, Peters GR: Gender does not affect the degree of duction of tirilazad clearance by Phenobarbital. European Journal of Clinical Pharmacology 1996, 50: 139-145. 10.1007/s002280050082CrossRef
108.
go back to reference Rambeck B, Specht U, Wolf P: Pharmacokinetic interactions of the new antiepileptic drugs. Clinical Pharmacokinetics 1996, 31: 309-324. 10.2165/00003088-199631040-00006CrossRef Rambeck B, Specht U, Wolf P: Pharmacokinetic interactions of the new antiepileptic drugs. Clinical Pharmacokinetics 1996, 31: 309-324. 10.2165/00003088-199631040-00006CrossRef
109.
go back to reference Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ: Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. Epilepsia 1996, 37: 253-257. 10.1111/j.1528-1157.1996.tb00021.xCrossRef Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ: Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. Epilepsia 1996, 37: 253-257. 10.1111/j.1528-1157.1996.tb00021.xCrossRef
110.
go back to reference Cropp JS, Bussey HI: A review of enzyme induction of warfarin metabolism with recommendations for patient management. Pharmacotherapy 1997, 17: 917-928. Cropp JS, Bussey HI: A review of enzyme induction of warfarin metabolism with recommendations for patient management. Pharmacotherapy 1997, 17: 917-928.
111.
go back to reference Jusko WJ: Role of tobacco smoking in pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 1978, 40: 67-39. Jusko WJ: Role of tobacco smoking in pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 1978, 40: 67-39.
112.
go back to reference Schein JR: Cigarette smoking and clinically significant drug interactions. Annals of Pharmacotherapy 1995, 29: 139-1148. Schein JR: Cigarette smoking and clinically significant drug interactions. Annals of Pharmacotherapy 1995, 29: 139-1148.
113.
go back to reference More lF, Beaune PH, Ratanasavanh D: Expression of cytochrome P-450 enzymes in cultured human hepatocytes. European Journal of Biochemistry 1990, 191: 437-444. 10.1111/j.1432-1033.1990.tb19140.xCrossRef More lF, Beaune PH, Ratanasavanh D: Expression of cytochrome P-450 enzymes in cultured human hepatocytes. European Journal of Biochemistry 1990, 191: 437-444. 10.1111/j.1432-1033.1990.tb19140.xCrossRef
114.
go back to reference Perrot N, Nalpas B, Yang CS, Beaune PH: Modulation of cytochrome P450 isozymes in human liver, by ethanol and drug intake. European Journal of Clinical Investigation 1989, 19: 549-555. 10.1111/j.1365-2362.1989.tb00273.xCrossRef Perrot N, Nalpas B, Yang CS, Beaune PH: Modulation of cytochrome P450 isozymes in human liver, by ethanol and drug intake. European Journal of Clinical Investigation 1989, 19: 549-555. 10.1111/j.1365-2362.1989.tb00273.xCrossRef
115.
go back to reference Kim RB, O'Shea D, Wilkinson GR: Relationship in healthy subjects between CYP2E1 genetic polymorphisms and the6-hydroxylation of chlorzoxazone: a putative measure of CYP2E1 activity. Pharmacogenetics 1994, 4: 162-165. 10.1097/00008571-199406000-00008CrossRef Kim RB, O'Shea D, Wilkinson GR: Relationship in healthy subjects between CYP2E1 genetic polymorphisms and the6-hydroxylation of chlorzoxazone: a putative measure of CYP2E1 activity. Pharmacogenetics 1994, 4: 162-165. 10.1097/00008571-199406000-00008CrossRef
116.
go back to reference Pelkonen O, Pasanen M, Kuha H: The effect of cigarette smoking on 7-ethoxyresorufin O-deethylase and other monooxygenase activities in human liver: analyses with monoclonal antibodies. British Journal of Clinical Pharmacology 1986, 22: 125-134. 10.1111/j.1365-2125.1986.tb05239.xCrossRef Pelkonen O, Pasanen M, Kuha H: The effect of cigarette smoking on 7-ethoxyresorufin O-deethylase and other monooxygenase activities in human liver: analyses with monoclonal antibodies. British Journal of Clinical Pharmacology 1986, 22: 125-134. 10.1111/j.1365-2125.1986.tb05239.xCrossRef
117.
go back to reference Sesardic D, Boobis AR, Edwards RJ, Davies DS: A form of cytochrome P450: in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol 1988,26(4):363-372. 10.1111/j.1365-2125.1988.tb03393.xCrossRef Sesardic D, Boobis AR, Edwards RJ, Davies DS: A form of cytochrome P450: in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol 1988,26(4):363-372. 10.1111/j.1365-2125.1988.tb03393.xCrossRef
118.
go back to reference Yun CH, Okerholm RA, Guengerich FP: Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450, 3A ( 4 ) in N-dealkylation and C-hydroxylation. Drug Metab Dispos 1993,21(3):403-409. Yun CH, Okerholm RA, Guengerich FP: Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450, 3A ( 4 ) in N-dealkylation and C-hydroxylation. Drug Metab Dispos 1993,21(3):403-409.
119.
go back to reference Rodrigues AD, Mulford DJ, Lee RD: In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P450:3A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices. Drug Metabolism and Disposition 1995, 23: 765-775. Rodrigues AD, Mulford DJ, Lee RD: In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P450:3A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices. Drug Metabolism and Disposition 1995, 23: 765-775.
120.
go back to reference Knodell RG, Browne DG, Gwozdz GP, Brian WR, Guengerich FP: Differential inhibition of individual human liver cytochromes P-450 by cimetidine. Gastroenterology 1991, 101: 1680-1691. Knodell RG, Browne DG, Gwozdz GP, Brian WR, Guengerich FP: Differential inhibition of individual human liver cytochromes P-450 by cimetidine. Gastroenterology 1991, 101: 1680-1691.
121.
go back to reference Jou MJ, Huang SC, Kiang FM, Lai MY, Chao PD: Comparison of the effects of cimetidine and ranitidine on the pharmacokinetics of disopyramide in man. J Pharm Pharmacol 1997,49(11):1072-1075. 10.1111/j.2042-7158.1997.tb06044.xCrossRef Jou MJ, Huang SC, Kiang FM, Lai MY, Chao PD: Comparison of the effects of cimetidine and ranitidine on the pharmacokinetics of disopyramide in man. J Pharm Pharmacol 1997,49(11):1072-1075. 10.1111/j.2042-7158.1997.tb06044.xCrossRef
122.
go back to reference Tanaka E, Nakamura K: Effects of H2-receptor antagonists on ethanol metabolism in Japanese volunteers. British Journal of Clinical Pharmacology 1988,26(1):96-99. 10.1111/j.1365-2125.1988.tb03370.xCrossRef Tanaka E, Nakamura K: Effects of H2-receptor antagonists on ethanol metabolism in Japanese volunteers. British Journal of Clinical Pharmacology 1988,26(1):96-99. 10.1111/j.1365-2125.1988.tb03370.xCrossRef
123.
go back to reference Arayne MS, Sultana N, Bibi Z: Grape Fruit Juice and Drug Interactions. Pak J Pharm Sci 2005,18(4):45-57. Arayne MS, Sultana N, Bibi Z: Grape Fruit Juice and Drug Interactions. Pak J Pharm Sci 2005,18(4):45-57.
124.
go back to reference Bailey DG, Arnold JM, Munoz C, Spence JD: Grapefruit juice – felodipine interaction: mechanism, predictability and effect of naringin. Clin Pharmacol Ther 1993, 53: 637-642. 10.1038/clpt.1993.84CrossRef Bailey DG, Arnold JM, Munoz C, Spence JD: Grapefruit juice – felodipine interaction: mechanism, predictability and effect of naringin. Clin Pharmacol Ther 1993, 53: 637-642. 10.1038/clpt.1993.84CrossRef
125.
go back to reference Ameer B, Weintraub RA: Drug interactions with grapefruit juice. Clinical Pharmacokinetics 1997, 33: 103-121. 10.2165/00003088-199733020-00003CrossRef Ameer B, Weintraub RA: Drug interactions with grapefruit juice. Clinical Pharmacokinetics 1997, 33: 103-121. 10.2165/00003088-199733020-00003CrossRef
126.
go back to reference Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ: Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin Pharmacol Ther 1995,58(2):127-131. 10.1016/0009-9236(95)90188-4CrossRef Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ: Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin Pharmacol Ther 1995,58(2):127-131. 10.1016/0009-9236(95)90188-4CrossRef
127.
go back to reference Bailey DG, Spence JD, Edgar B, Bayliff CD: Ethanol enhances the hemodynamic effects of felodipine. Clin Invest Med 1989,12(6):357-362. Bailey DG, Spence JD, Edgar B, Bayliff CD: Ethanol enhances the hemodynamic effects of felodipine. Clin Invest Med 1989,12(6):357-362.
128.
go back to reference Zakia Bibi: Effect of fruit juices on the availability of cephalosporins and quinolones antibiotics. PhD thesis. Karachi University, Chemistry; 2008. Zakia Bibi: Effect of fruit juices on the availability of cephalosporins and quinolones antibiotics. PhD thesis. Karachi University, Chemistry; 2008.
129.
go back to reference Song BJ: Ethanol-inducible cytochrome P450: (CYP2E1): biochemistry, molecular biology and clinical relevance Up-Date. Alcoholism, Clinical and Experimental Research 1996,20(Suppl 8):138A-146A. 10.1111/j.1530-0277.1996.tb01764.xCrossRef Song BJ: Ethanol-inducible cytochrome P450: (CYP2E1): biochemistry, molecular biology and clinical relevance Up-Date. Alcoholism, Clinical and Experimental Research 1996,20(Suppl 8):138A-146A. 10.1111/j.1530-0277.1996.tb01764.xCrossRef
130.
go back to reference Gugler R, Jensen JC: Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology 1985, 89: 1235-1241. Gugler R, Jensen JC: Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology 1985, 89: 1235-1241.
131.
go back to reference Andersson T, Cederberg C, Edvardsson G, Heggelund A, Lundborg P: Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther 1990,47(1):79-85. 10.1038/clpt.1990.12CrossRef Andersson T, Cederberg C, Edvardsson G, Heggelund A, Lundborg P: Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther 1990,47(1):79-85. 10.1038/clpt.1990.12CrossRef
132.
go back to reference Andersson T: Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996,31(1):9-28. 10.2165/00003088-199631010-00002CrossRef Andersson T: Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996,31(1):9-28. 10.2165/00003088-199631010-00002CrossRef
133.
go back to reference Kivisto KT, Neuvonen PJ, Klotz U: Inhibition of terfenadine metabolism. Pharmacokinetic and pharmacodynamic consequences. Clinical Pharmacokinetics 1994, 27: 1-5. 10.2165/00003088-199427010-00001CrossRef Kivisto KT, Neuvonen PJ, Klotz U: Inhibition of terfenadine metabolism. Pharmacokinetic and pharmacodynamic consequences. Clinical Pharmacokinetics 1994, 27: 1-5. 10.2165/00003088-199427010-00001CrossRef
134.
go back to reference Godin JR, Sketris IS, Belitsky P: Erythromycin-cyclosporin interaction. Drug Intell Clin Pharm 1986,20(6):504-505. Godin JR, Sketris IS, Belitsky P: Erythromycin-cyclosporin interaction. Drug Intell Clin Pharm 1986,20(6):504-505.
135.
go back to reference Brian WR, Sari MA, Iwasaki M, Shimada T, Kaminsky LS, Guengerich FP: Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in SaccharoI?myces cerevisiae. Biochemistry 1990, 29: 11280-11292. 10.1021/bi00503a018CrossRef Brian WR, Sari MA, Iwasaki M, Shimada T, Kaminsky LS, Guengerich FP: Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in SaccharoI?myces cerevisiae. Biochemistry 1990, 29: 11280-11292. 10.1021/bi00503a018CrossRef
136.
go back to reference Gillam EM, Guo Z, Ueng YF: Expression of cytochrome P450: 3A5 in Escherichia coli: effects of 5 modification,purification, spectral characterization, reconstitution conditions, and catalytic activities. Archives of Biochemistry and Biophysics 1995, 317: 374-384. 10.1006/abbi.1995.1177CrossRef Gillam EM, Guo Z, Ueng YF: Expression of cytochrome P450: 3A5 in Escherichia coli: effects of 5 modification,purification, spectral characterization, reconstitution conditions, and catalytic activities. Archives of Biochemistry and Biophysics 1995, 317: 374-384. 10.1006/abbi.1995.1177CrossRef
137.
go back to reference Kronbach T, Fischer V, Meyer UA: Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with otherdrugs. Clin Pharmacol Ther 1988,43(6):630-635. 10.1038/clpt.1988.87CrossRef Kronbach T, Fischer V, Meyer UA: Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with otherdrugs. Clin Pharmacol Ther 1988,43(6):630-635. 10.1038/clpt.1988.87CrossRef
138.
go back to reference Combalbert J, Fabre I, Fabre G: Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metab Dispos 1989,17(2):197-207. Combalbert J, Fabre I, Fabre G: Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metab Dispos 1989,17(2):197-207.
139.
go back to reference Aoyama T, Yamano S, Waxman DJ: Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. Journal of Biological Chemistry 1989, 264: 10388-10395. Aoyama T, Yamano S, Waxman DJ: Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. Journal of Biological Chemistry 1989, 264: 10388-10395.
140.
go back to reference Lucey MR, Kolars JC, Merion RM, Campbell DA, Aldrich M, Watkins PB: Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450 IIIA. Lancet 1990, 335: 11-15. 10.1016/0140-6736(90)90137-TCrossRef Lucey MR, Kolars JC, Merion RM, Campbell DA, Aldrich M, Watkins PB: Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450 IIIA. Lancet 1990, 335: 11-15. 10.1016/0140-6736(90)90137-TCrossRef
141.
go back to reference Breckenridge A: Clinical significance ofteractions with antifungal agents. British Journal of Dermatology 1992,19(126 Suppl 39):22. Breckenridge A: Clinical significance ofteractions with antifungal agents. British Journal of Dermatology 1992,19(126 Suppl 39):22.
142.
go back to reference Murphy R, Swartz R, Watkins PB: Severe acetaminophen toxicity in a patient receiving isoniazid. Annals of Internal Medicine 1990, 113: 799-800. 10.7326/0003-4819-113-10-799CrossRef Murphy R, Swartz R, Watkins PB: Severe acetaminophen toxicity in a patient receiving isoniazid. Annals of Internal Medicine 1990, 113: 799-800. 10.7326/0003-4819-113-10-799CrossRef
143.
go back to reference Guengerich FP, Brian WR, Iwasaki M, Sari MA, Baarnhielm C, Berntsson P: Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. Journal of Medicinal Chemistry 1991, 34: 1838-1844. 10.1021/jm00110a012CrossRef Guengerich FP, Brian WR, Iwasaki M, Sari MA, Baarnhielm C, Berntsson P: Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. Journal of Medicinal Chemistry 1991, 34: 1838-1844. 10.1021/jm00110a012CrossRef
144.
go back to reference Hunt SN, Jusko WJ, Yurchak AM: Effect of smoking on theophylline disposition. Clinical Pharmacology and Therapeutics 1976,19(1):546-551.CrossRef Hunt SN, Jusko WJ, Yurchak AM: Effect of smoking on theophylline disposition. Clinical Pharmacology and Therapeutics 1976,19(1):546-551.CrossRef
145.
go back to reference Sesardic D, Boobis AR, Edwards RJ, Davies DS: A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. British Journal of Clinical Pharmacology 1988, 26: 363-372. 10.1111/j.1365-2125.1988.tb03393.xCrossRef Sesardic D, Boobis AR, Edwards RJ, Davies DS: A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. British Journal of Clinical Pharmacology 1988, 26: 363-372. 10.1111/j.1365-2125.1988.tb03393.xCrossRef
146.
go back to reference Lieber CS, Lasker JM, Alderman J, Leo MA: The microsomal ethanol oxidizing system and its interaction with other drugs,carcinogens, and vitamins. Annals of the New York Academy of Sciences 1987, 492: 11-24. 10.1111/j.1749-6632.1987.tb48649.xCrossRef Lieber CS, Lasker JM, Alderman J, Leo MA: The microsomal ethanol oxidizing system and its interaction with other drugs,carcinogens, and vitamins. Annals of the New York Academy of Sciences 1987, 492: 11-24. 10.1111/j.1749-6632.1987.tb48649.xCrossRef
147.
go back to reference Lieber CS: Mechanisms of ethanol-drug-nutrition interactions. J Toxicol Clin Toxicol 1994,32(6):631-681. 10.3109/15563659409017974CrossRef Lieber CS: Mechanisms of ethanol-drug-nutrition interactions. J Toxicol Clin Toxicol 1994,32(6):631-681. 10.3109/15563659409017974CrossRef
148.
go back to reference Lieber CS: Susceptibility to alcohol-related liver injury. Alcohol Alcohol Suppl 1994, 2: 315-326. Lieber CS: Susceptibility to alcohol-related liver injury. Alcohol Alcohol Suppl 1994, 2: 315-326.
149.
go back to reference Kitson KE: Ethanol and acetaldehyde metabolism: past, present and future. Alcoholism, Clinical and Experimental Research 1996,20(Suppl 8):82A-92A. 10.1111/j.1530-0277.1996.tb01752.xCrossRef Kitson KE: Ethanol and acetaldehyde metabolism: past, present and future. Alcoholism, Clinical and Experimental Research 1996,20(Suppl 8):82A-92A. 10.1111/j.1530-0277.1996.tb01752.xCrossRef
150.
go back to reference Asai H, Imaoka S: Microsomal ethanol oxidizing system activity by human hepatic cytochrome P450s. J Pharmacol Exp Ther 1996,277(2):1004-1009. Asai H, Imaoka S: Microsomal ethanol oxidizing system activity by human hepatic cytochrome P450s. J Pharmacol Exp Ther 1996,277(2):1004-1009.
Metadata
Title
Role of cytochrome P450 in drug interactions
Author
Zakia Bibi
Publication date
01-12-2008
Publisher
BioMed Central
Published in
Nutrition & Metabolism / Issue 1/2008
Electronic ISSN: 1743-7075
DOI
https://doi.org/10.1186/1743-7075-5-27

Other articles of this Issue 1/2008

Nutrition & Metabolism 1/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.